Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Sema4 Holdings Corp. (WGS) Insider Trading Activity

    Healthcare • Health Information Services • 1,000 employees

    GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

    Total Value

    -$110,477,342.70

    Total Shares

    -1,931,660

    Average Trade Value

    -$1,753,608.61

    Most Active Insider

    Icahn School Of Medicine At Mount Sinai

    Total Activity: $75,328,723

    Largest Single Transaction

    $64,935,000

    by Icahn School Of Medicine At Mount Sinai on Oct 31, 2024

    30-Day Activity

    8 Transactions

    Volume: 15,929 shares
    Value: $1,418,567

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Executive Officer
    Dec 16, 2024 18,750 $10,000 81,647 (+23.0%) Exercise/Conversion
    Chief Financial Officer
    Dec 16, 2024 7,197 $10,000 31,928 (+22.5%) Exercise/Conversion
    Chief Executive Officer
    Dec 16, 2024 10,501 $805,995 71,146 (-14.8%) Sale
    Chief Financial Officer
    Dec 16, 2024 3,728 $286,139 28,200 (-13.2%) Sale
    Chief Financial Officer
    Dec 9, 2024 2,462 $10,000 25,868 (+9.5%) Exercise/Conversion
    Chief Executive Officer
    Dec 9, 2024 3,661 $279,598 62,897 (-5.8%) Sale
    Chief Executive Officer
    Dec 9, 2024 6,547 $10,000 66,558 (+9.8%) Exercise/Conversion
    Chief Financial Officer
    Dec 9, 2024 1,137 $86,836 24,731 (-4.6%) Sale
    Nov 18, 2024 126,782 $8,973,059 2,719,692 (-4.7%) Sale
    Chief Executive Officer
    Nov 18, 2024 459 $31,183 81,059 (-0.6%) Sale
    Chief Executive Officer
    Nov 18, 2024 8,580 $608,418 63,142 (-13.6%) Sale
    Chief Executive Officer
    Nov 18, 2024 3,151 $217,349 77,908 (-4.0%) Sale
    Chief Executive Officer
    Nov 18, 2024 800 $53,283 81,518 (-1.0%) Sale
    Chief Executive Officer
    Nov 18, 2024 3,131 $224,905 60,011 (-5.2%) Sale
    Chief Executive Officer
    Nov 18, 2024 6,186 $433,952 71,722 (-8.6%) Sale
    Chief Executive Officer
    Nov 15, 2024 2,043 $149,045 83,888 (-2.4%) Sale
    Chief Executive Officer
    Nov 15, 2024 5,497 $377,386 99,929 (-5.5%) Sale
    Chief Executive Officer
    Nov 15, 2024 4,800 $334,439 95,129 (-5.0%) Sale
    Chief Executive Officer
    Nov 15, 2024 60 $4,460 82,318 (-0.1%) Sale
    Nov 15, 2024 20,359 $1,420,663 2,846,474 (-0.7%) Sale
    Chief Executive Officer
    Nov 15, 2024 1,958 $139,977 85,931 (-2.3%) Sale
    Chief Executive Officer
    Nov 15, 2024 7,240 $511,985 87,889 (-8.2%) Sale
    Chief Executive Officer
    Nov 15, 2024 1,510 $111,302 82,378 (-1.8%) Sale
    Oct 31, 2024 865,800 $64,935,000 2,866,833 (-30.2%) Sale
    Chief Financial Officer
    Oct 29, 2024 274 $18,248 44,951 (-0.6%) Sale
    Chief Executive Officer
    Oct 29, 2024 2,154 $143,456 105,426 (-2.0%) Sale
    Chief Financial Officer
    Oct 29, 2024 753 $0 45,225 (+1.7%) Exercise/Conversion
    Chief Executive Officer
    Oct 29, 2024 3,874 $0 107,580 (+3.6%) Exercise/Conversion
    Oct 15, 2024 130 $0 7,983 (+1.6%) Exercise/Conversion
    Oct 15, 2024 130 $0 73,744 (+0.2%) Exercise/Conversion
    Chief Financial Officer
    Sep 16, 2024 7,197 $0 47,107 (+15.3%) Exercise/Conversion
    Chief Financial Officer
    Sep 16, 2024 2,635 $99,050 44,472 (-5.9%) Sale
    Chief Executive Officer
    Sep 16, 2024 10,501 $394,733 103,706 (-10.1%) Sale
    Chief Executive Officer
    Sep 16, 2024 18,750 $10,000 114,207 (+16.4%) Exercise/Conversion
    Chief Executive Officer
    Sep 9, 2024 6,546 $10,000 99,096 (+6.6%) Exercise/Conversion
    Chief Financial Officer
    Sep 9, 2024 2,462 $10,000 40,805 (+6.0%) Exercise/Conversion
    Chief Executive Officer
    Sep 9, 2024 3,639 $121,288 95,457 (-3.8%) Sale
    Chief Financial Officer
    Sep 9, 2024 895 $29,830 39,910 (-2.2%) Sale
    Chief Financial Officer
    Sep 3, 2024 262 $8,308 38,343 (-0.7%) Sale
    Chief Financial Officer
    Sep 1, 2024 717 $10,000 38,605 (+1.9%) Exercise/Conversion
    Aug 19, 2024 50,000 $1,724,520 2,646,972 (-1.9%) Sale
    Aug 16, 2024 50,000 $1,714,850 2,696,972 (-1.9%) Sale
    Aug 15, 2024 39,824 $1,317,505 2,746,972 (-1.4%) Sale
    Aug 13, 2024 24,987 $868,503 2,786,796 (-0.9%) Sale
    Aug 12, 2024 59,787 $2,029,811 2,811,783 (-2.1%) Sale
    Aug 8, 2024 100,000 $3,182,380 2,871,570 (-3.5%) Sale
    Aug 6, 2024 12,994 $381,427 2,971,570 (-0.4%) Sale
    Jul 31, 2024 88,839 $2,976,346 2,984,564 (-3.0%) Sale
    Chief Executive Officer
    Jul 29, 2024 2,154 $72,245 92,550 (-2.3%) Sale
    Chief Financial Officer
    Jul 29, 2024 274 $9,190 37,888 (-0.7%) Sale
    Chief Executive Officer
    Jul 29, 2024 3,874 $10,000 94,704 (+4.1%) Exercise/Conversion
    Jul 29, 2024 50,000 $1,692,890 3,073,403 (-1.6%) Sale
    Chief Financial Officer
    Jul 29, 2024 753 $10,000 38,162 (+2.0%) Exercise/Conversion
    Jul 26, 2024 60,000 $2,031,258 3,123,403 (-1.9%) Sale
    Jul 24, 2024 75,000 $2,529,105 3,183,403 (-2.4%) Sale
    Jul 23, 2024 75,000 $2,509,245 3,258,403 (-2.3%) Sale
    Jul 22, 2024 50,000 $1,630,440 3,333,403 (-1.5%) Sale
    Jul 19, 2024 25,000 $807,250 3,383,403 (-0.7%) Sale
    Jul 17, 2024 25,000 $823,188 3,408,403 (-0.7%) Sale
    Jul 5, 2024 36,118 $1,020,016 3,433,403 (-1.1%) Sale
    Jul 3, 2024 14,082 $397,491 3,469,521 (-0.4%) Sale
    Jul 2, 2024 25,000 $728,095 3,483,603 (-0.7%) Sale
    Jul 1, 2024 50,000 $1,331,700 3,508,603 (-1.4%) Sale